Waters Corporation

Report azionario NYSE:WAT

Capitalizzazione di mercato: US$33.6b

Waters Crescita futura

Criteri Future verificati 4/6

Waters prevede che gli utili e i ricavi cresceranno rispettivamente di 24% e 15.4% all'anno. Si prevede che l'EPS crescerà di 21.5% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 13.8% in 3 anni.

Informazioni chiave

24.0%

Tasso di crescita degli utili

21.47%

Tasso di crescita dell'EPS

Life Sciences crescita degli utili16.9%
Tasso di crescita dei ricavi15.4%
Rendimento futuro del capitale proprio13.84%
Copertura analitica

Good

Ultimo aggiornamento06 May 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Aggiornamento dell'analisi • May 01

WAT: New Instrument Launches And Reorganized Divisions Will Support Future Upside

Analysts have trimmed their price target on Waters from $480 to $470, citing updated assumptions for significantly higher revenue growth at 37.91%, a profit margin of 17.88%, a prospective P/E of 47.70 and a discount rate of 7.89%. What's in the News Waters plans to globally launch the omniDAWN Multi Angle Light Scattering Photometer in summer 2026, targeting UHPLC and UPLC workflows for absolute molar mass and size measurements across complex analytes such as protein aggregates, viral vectors, lipid nanoparticles, and advanced materials (Key Developments).
Aggiornamento dell'analisi • Apr 17

WAT: Reorganization And Product Pipeline Will Likely Keep Upside In Check

Analysts have kept their price target for Waters steady at $330.00, citing updated assumptions for slightly higher revenue growth, a wider profit margin, and a higher future P/E multiple as the key drivers behind the unchanged fair value view. What's in the News Launched the Waters omniDAWN Multi-Angle Light Scattering Photometer for UHPLC and UPLC workflows, targeting absolute molar mass and size measurements for complex analytes such as protein aggregates, viral vectors, lipid nanoparticles, and advanced materials.
Aggiornamento dell'analisi • Apr 03

WAT: New Four Division Model And Materials Focus Will Support Higher Profitability

Analysts have reduced their price target on Waters by about $5 to $393, reflecting small adjustments to fair value assumptions, discount rate, revenue growth, profit margin and future P/E inputs. What's in the News Waters launched the TA Instruments ARES-G3 Rheometer, a next generation system that captures up to 25,000 data points per second, aims to shorten standard test times by up to 80%, and is available for order as part of the materials characterization portfolio (Key Developments).
Aggiornamento dell'analisi • Mar 20

WAT: New Four Division Model Will Support Higher Long Term Profitability

Analysts have kept their price target for Waters steady at $398.05. This reflects updated views on a slightly lower discount rate, modestly adjusted revenue growth expectations, a higher projected profit margin, and a reduced future P/E assumption.
Seeking Alpha • Mar 10

Waters: Doing Well, Acquired Activities Not So Much

Summary Waters' shares have retreated to the $300 level, presenting a renewed buying opportunity after initial post-acquisition gains evaporated. The $17.5B acquisition of Becton, Dickinson's Biosciences & Diagnostics Solutions expands Waters scale, though acquired business growth appears soft versus initial expectations. Waters guides 2026 sales to $6.405–$6.455B and adjusted EPS to $14.30–$14.50, reflecting early synergies and manageable leverage. At 21x earnings, Waters is not historically cheap, but synergy potential and deleveraging support a more upbeat outlook at current levels. Read the full article on Seeking Alpha
Aggiornamento dell'analisi • Mar 05

WAT: New Four Division Structure Will Support Higher Long Term Earnings

Analysts have nudged their price target for Waters higher to $398.05 from $394.68, reflecting updated assumptions that combine a higher revenue growth outlook, a lower projected profit margin, and a richer future P/E multiple. What's in the News Waters has closed a transaction and reorganized into four divisions, aligning its operations with high volume testing in regulated applications and adjacent markets such as therapeutics, food, environmental testing, and specialty diagnostics (Key Developments).
Aggiornamento dell'analisi • Feb 19

WAT: Reorganization And Margin Pressure Will Likely Cap Upside For Now

Analysts now mark their price target for Waters at $330, down from $349, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E that change their overall valuation framework. What's in the News Waters closed a transaction and reorganized into four divisions focused on high-volume testing and adjacent markets, now grouped as Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences (company announcement).
Aggiornamento dell'analisi • Feb 05

WAT: New Detector Launch And Higher Margins Will Likely Disappoint Optimists

Analysts have modestly lifted their price target for Waters to about $349, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E as the key drivers of this small adjustment from roughly $348.15. What's in the News Waters has scheduled a special or extraordinary shareholders meeting for January 27, 2026, to be held online via proxydocs.com/wat in the United States (Key Developments).
Aggiornamento dell'analisi • Jan 22

WAT: New Detector Launch And Stable Margins Will Support Future Upside

Analysts kept their price target for Waters steady at US$480.00, with only very small tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions, reflecting fine-tuning rather than a major shift in their view. What's in the News Waters scheduled a special or extraordinary shareholders meeting for January 27, 2026, to be held via proxydocs.com/wat in the United States (company event filing).
Aggiornamento dell'analisi • Jan 08

WAT: Higher Margins And New Product Launch Will Support Future Upside

Analysts have lifted their price target on Waters to US$480 from about US$424, citing updated assumptions for slightly higher revenue growth, profit margins near 26%, and a modestly higher future P/E multiple. What's in the News Waters scheduled a special or extraordinary shareholders meeting for January 27, 2026, to be held online via proxydocs.com/wat (Special/Extraordinary Shareholders Meeting).
Articolo di analisi • Jan 04

Estimating The Intrinsic Value Of Waters Corporation (NYSE:WAT)

Key Insights Waters' estimated fair value is US$362 based on 2 Stage Free Cash Flow to Equity Waters' US$382 share...
Aggiornamento dell'analisi • Dec 25

WAT: Future Product Expansion Will Likely Fail To Justify Current Optimism

Analysts have raised their price target on Waters from 300.00 dollars to 348.15 dollars, citing slightly stronger expectations for revenue growth, profit margins, and future valuation multiples. What's in the News Launched a new Charged Aerosol Detector optimized for Empower Software, expanding capabilities for measuring analytes with little or no UV absorption across pharmaceuticals, food, and environmental testing, with shipments expected by April 2026 (company product announcement).
Aggiornamento dell'analisi • Dec 10

WAT: Future Margin Gains And New Instruments Will Support Measured Earnings Outlook

Narrative Update on Waters Analysts have modestly raised their price target on Waters by approximately $6 per share, reflecting slightly lower discount rate assumptions, a small improvement in projected profit margins, and a marginally higher future P/E multiple that together support a higher fair value estimate. What's in the News Launched a new Charged Aerosol Detector, purpose built for Empower chromatography software, expanding Waters portfolio of LC detectors and strengthening its position in compliant, high sensitivity analysis for low UV analytes, with shipments expected by April 2026 (Key Developments) Unveiled the Xevo Charge Detection Mass Spectrometer to enable high resolution characterization of very large biomolecules that are central to next generation therapeutics, leveraging technology acquired from Indiana University and Megadalton Solutions (Key Developments) Raised full year 2025 guidance and now expects constant currency sales growth of 6.7% to 7.3% and GAAP EPS of 11.10 to 11.20 dollars per diluted share (Key Developments) Issued new guidance for the fourth quarter of 2025, targeting constant currency sales growth of 5.0% to 7.0% and GAAP EPS of 4.10 to 4.20 dollars per diluted share (Key Developments) Completed its multi year share repurchase program announced in January 2019, buying back more than 15.1 million shares for approximately 3.8 billion dollars in total consideration (Key Developments) Valuation Changes The fair value estimate has risen slightly to approximately $395 per share from about $389 per share, reflecting modest valuation upside.
Aggiornamento dell'analisi • Nov 26

WAT: Future Margins And Expanded Guidance Will Offset Slower Revenue Trends

Narrative Update on Waters: Analyst Price Target Revision Analysts have raised their price target for Waters, increasing the fair value estimate by $5.71 to $388.58. This revision is attributed to improved profit margin projections, even as revenue growth expectations have slowed.
Aggiornamento dell'analisi • Nov 07

WAT: Revenue Momentum And Expanded Guidance Will Balance Margin Risks Ahead

Analysts have raised their price target for Waters from $355.74 to $382.87. They cite significantly higher expected revenue growth, which outweighs a slight decrease in projected profit margins.
Aggiornamento dell'analisi • Oct 23

Emerging Technologies And Share Repurchases Will Support Long-Term Market Opportunities

Narrative Update on Waters Analysts have slightly raised their price target for Waters from $351.07 to $355.74. This change is attributed to modest improvements in projected revenue growth and fair value estimates.
Aggiornamento dell'analisi • Oct 09

Pharmaceutical R&D And Merger Will Unlock Future Market Potential

Analysts have raised their price target for Waters to $351.07 from $347.14, citing expectations of stronger profit margins and steady revenue growth ahead. What's in the News Waters Corporation raised its earnings guidance for the full year 2025 and projects constant currency sales growth between 5.5% and 7.5%.
Articolo di analisi • Sep 19

Risks To Shareholder Returns Are Elevated At These Prices For Waters Corporation (NYSE:WAT)

Waters Corporation's ( NYSE:WAT ) price-to-earnings (or "P/E") ratio of 27.6x might make it look like a sell right now...
Aggiornamento dell'analisi • Sep 04

Pharmaceutical R&D And Merger Will Unlock Future Market Potential

With no changes in revenue growth expectations or discount rate, Waters’ fair value estimate remains stable, as reflected in the unchanged consensus analyst price target of $350.24. What's in the News Completed buyback program with 15,195,844 shares repurchased for $3,790.62 million, representing 22.96% of shares.
Articolo di analisi • Jul 24

Are Investors Undervaluing Waters Corporation (NYSE:WAT) By 36%?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Waters fair value estimate is US$465 Waters is estimated to be...
Articolo di analisi • Jul 06

These 4 Measures Indicate That Waters (NYSE:WAT) Is Using Debt Reasonably Well

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Articolo di analisi • May 07

Waters Corporation's (NYSE:WAT) Shares May Have Run Too Fast Too Soon

With a price-to-earnings (or "P/E") ratio of 30.7x Waters Corporation ( NYSE:WAT ) may be sending very bearish signals...
Seeking Alpha • Feb 21

Waters Corporation: Instrument Replacement Cycle Momentum, But Valuation Is A Concern

Summary Waters Corp reported better-than-expected Q4'24 and FY'24 results, driven by strong performance in academia, government, and pharma segments, despite FX headwinds impacting gross margins. The company anticipates continued growth in 2025, with projected revenue growth between 4.5% and 7%, supported by emerging markets like India and high-growth areas like GLP-1 and PFAS testing. Risks include elevated valuations and limited opportunities for cash deployment, making buybacks less attractive; current valuation appears challenging compared to historical averages and peers. I rate Waters Corp as a 'hold' due to solid recovery and growth potential, but caution investors to consider the premium pricing relative to value. Read the full article on Seeking Alpha
Seeking Alpha • Jan 29

Weighing In On Waters Corporation: Facing A Valuation Headwind

Summary Today, we take a more in-depth look at Waters Corporation, which provides analytical workflow solutions, primarily to the Pharma and Industrial industries. WAT stock has surged 35% since July lows, but analysts are growing increasingly cautious due to valuation concerns, with mixed ratings and tepid price targets. From a historical perspective, the equity now trades at the very top of its historical P/S and P/E ratios. Can WAT shares rally with this valuation headwind? An analysis of Waters Corporation follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Nov 13

Waters Corp: Short Reinvestment Runway Diminishes High Multiples

Summary Despite a 13% stock appreciation, I maintain a neutral stance on Waters Corporation due to factors outlined in this report. Q3 FY'24 results show mixed regional performance, with China sales still a drag on performance. Opportunities to redeploy surplus funds at an advantage appear limited, reducing compounding ability. Read the full article on Seeking Alpha
Seeking Alpha • Aug 15

Waters Corp.: Embedded Expectations High Under Present Conditions

Summary Waters continues to present with high-quality business characteristics, including high returns on capital employed and loads of freely available cash. Embedded expectations remain exquisitely high, calling for outsized performance in a time when business returns may be contracting. Present multiples demand high compounding rate of operating capital, which reduces the margin of safety. Reiterate hold. Read the full article on Seeking Alpha
Seeking Alpha • May 24

Waters Corporation: Still Struggling A Bit

Summary Waters Corporation reported mediocre first quarter results with the top and bottom line declining. According to fiscal 2024 guidance, the company is still not expecting growth but due to the wide economic moat, we should be optimistic for long-term growth. At this point, Waters Corporation is fairly valued at best and still not a great investment. Read the full article on Seeking Alpha
Seeking Alpha • Mar 11

Waters Corporation: A Great (Share Price) Run

Summary Waters Corporation stock has seen strong momentum, rising over $100 per share in a short period of time. The company serves regulated markets with high-quality solutions and has a recurring revenue business model. After a tough 2023 and non-convincing outlook for 2024, I am surprised by the share price momentum, making me pleased to take profits in Waters Corporation stock here. Read the full article on Seeking Alpha
Seeking Alpha • Dec 28

Waters Corporation: High Quality Niche Company In Mass Spectrometry

Summary Waters is a niche player in the liquid chromatography, mass spectrometry, and thermal analysis markets, with a simple and profitable business model. The company's focus on product innovation and acquisitions contributes to its growth and competitive advantage. However, Waters faces headwinds in the Chinese market, which may impact its growth in the near term. Read the full article on Seeking Alpha

Previsioni di crescita degli utili e dei ricavi

NYSE:WAT - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20287,5341,3481,5341,91815
12/31/20277,0941,3521,3781,79121
12/31/20266,4359871,2051,15621
4/4/20263,770450264390N/A
12/31/20253,165643540653N/A
9/27/20253,106649602728N/A
6/28/20253,046661619745N/A
3/29/20252,983657619759N/A
12/31/20242,958638620762N/A
9/28/20242,905623620752N/A
6/29/20242,877596561705N/A
3/30/20242,909604514669N/A
12/31/20232,956642442603N/A
9/30/20232,995653390571N/A
7/1/20232,992675387572N/A
4/1/20232,966689425610N/A
12/31/20222,972708428612N/A
10/1/20222,950697465631N/A
7/2/20222,901702477641N/A
4/2/20222,868705565727N/A
12/31/20212,786693579747N/A
10/2/20212,736695626797N/A
7/3/20212,671660642802N/A
4/3/20212,509616697857N/A
12/31/20202,365522618791N/A
9/26/20202,295504536715N/A
6/27/20202,278515495691N/A
3/28/20202,358537N/A619N/A
12/31/20192,407592N/A643N/A
9/28/20192,405577N/A633N/A
6/29/20192,406580N/A631N/A
3/30/20192,403591N/A604N/A
12/31/20182,420594N/A604N/A
9/29/20182,39255N/A615N/A
6/30/20182,38051N/A623N/A
3/31/20182,34227N/A699N/A
12/31/20172,30920N/A698N/A
9/30/20172,251548N/A679N/A
7/1/20172,212537N/A674N/A
4/1/20172,190533N/A656N/A
12/31/20162,167522N/A643N/A
10/1/20162,125498N/A623N/A
7/2/20162,099490N/A613N/A
4/2/20162,057467N/A567N/A
12/31/20152,042469N/A573N/A
10/3/20152,040469N/A568N/A
7/4/20152,032467N/A557N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di WAT ( 24% all'anno) è superiore al tasso di risparmio ( 3.5% ).

Guadagni vs Mercato: Si prevede che gli utili di WAT ( 24% all'anno) cresceranno più rapidamente del mercato US ( 16.4% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di WAT cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di WAT ( 15.4% all'anno) crescerà più rapidamente del mercato US ( 11.4% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di WAT ( 15.4% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di WAT sarà basso tra 3 anni ( 13.8 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/06 06:14
Prezzo dell'azione a fine giornata2026/05/06 00:00
Utili2026/04/04
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Waters Corporation è coperta da 39 analisti. 21 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Catherine Ramsey SchulteBaird
Charles ButlerBarclays
Luke SergottBarclays